Nexavar beneficial in liver cancer regardless of prognostic factors
Nexavar treatment consistently showed benefit in hepatocellular carcinoma regardless of prognostic factors, according to results of a recently published study.
“Although analyses of potential predictive factors for sorafenib benefit have been attempted with data from single-arm, observational studies, the lack of a placebo arm in these trials has prevented proper differentiation between prognostic and predictive markers,”
Jordi Bruix, MD, from the BLCL Hospital Clinic Barcelona, Spain, and colleagues wrote. “Our analysis showed a consistent OS benefit with sorafenib treatment compared with placebo irrespective of patient baseline characteristics, subgroup or prognostic factors for survival.”
Continue reading.....
Free registration may be required
